💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Technetium Mertiatide

CHEMBL2111131 Phase 4 معتمد Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Technetium mertiatide (99mTc-MAG3, mercaptoacetylglycylglycylglycine) is a tubular secretion-based renal radiopharmaceutical that is actively secreted by proximal renal tubules, providing dynamic scintigraphic assessment of renal perfusion, function, and drainage. It is used to measure differential renal function, evaluate obstructive uropathy, assess renal transplant function, and diagnose renovascular hypertension. Its high renal extraction fraction and rapid clearance make it superior to glomerular agents in patients with impaired renal function.

المجالات العلاجية

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Breast Cancer Prostate Cancer Colorectal Cancer

آلية العمل

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Technetium mertiatide (99mTc-MAG3, mercaptoacetylglycylglycylglycine) is a tubular secretion-based renal radiopharmaceutical that is actively secreted by proximal renal tubules, providing dynamic scintigraphic assessment of renal perfusion, function, and drainage. It is used to measure differential renal function, evaluate obstructive uropathy, assess renal transplant function, and diagnose renovascular hypertension. Its high renal extraction fraction and rapid clearance make it superior to glomerular agents in patients with impaired renal function.

Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.

Yes, Technetium Mertiatide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2111131. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.